Oct, 1, 2023

Vol.30 No.2, pp. 84-88

Current Issue Archives
Search
Advanced Search
Editorial Office

Review

  • Korean Journal of Biological Psychiatry
  • Volume 23(1); 2016
  • Article

Review

Korean Journal of Biological Psychiatry 2016;23(1):18-23. Published online: Jan, 1, 2016

Abstract PDF Full Text

Mammalian Target of Rapamycin Signaling Pathways and Depression

  • Jung Goo Lee, MD1,2,3;Mi Kyong Seo, PhD2;Sung Woo Park, PhD2,3; and Young Hoon Kim, MD1,2,3;
    1;Department of Psychiatry, Haeundae Paik Hospital and College of Medicine, Inje University, Busan, 2;Paik Institute for Clinical Research, Inje University College of Medicine, Busan, 3;Department of Health Science and Technology, Graduate School of Inje University, Busan, Korea
Abstract

Depression is a complicated psychiatric illness with severe consequences. Despite recent advanced achievements of molecular neurobiology, pathophysiology of depression has not been well elucidated. Among new findings of pathophysiology of depression, the possible fast antidepressant effect by N-methyl-D-asparate receptor antagonist, such as ketamine, is regarded as a promising treatment target of depression. Ketamine stimulates the mammalian target of rapamycin (mTOR) signaling pathway and activation of mTOR signaling pathway may be a key mechanism of the antidepressant effect of ketamine. Thus, this review describes the role of mTOR signaling in the pathophysiology of depression and developing a new treatment target of depression.

Keywords Depression;Mammalian target of rapamycin;N-methyl-D-asparate receptor;Ketamine;Pathophysiology.